中药辅助治疗降低类风湿关节炎患者缺血性卒中风险
本研究为回顾性队列研究,利用台湾全民健康保险研究数据库1997至2011年数据,纳入1997至2010年新诊断类风湿关节炎患者,比较中药联合西药与单用西药对缺血性卒中风险的影响。经1:1匹配后,中药组与非中药组各4148例;中药组缺血性卒中风险显著降低(aHR 0.67,95%CI 0.52-0.86),使用中药超过30天者风险更低(aHR 0.61,95%CI 0.40-0.91)。桂枝芍药知母汤、舒筋活血汤和独活寄生汤可能与降低缺血性卒中风险相关。
要点
- 类风湿关节炎患者在西药基础上加用中药,缺血性卒中风险显著降低。
- 中药使用超过30天者,缺血性卒中风险进一步降低。
- 桂枝芍药知母汤、舒筋活血汤、独活寄生汤可能与降低风险相关。
核心结论
- 中药联合西药治疗与类风湿关节炎患者缺血性卒中风险降低相关,尤其是使用中药超过30天者。
研究设计与样本
- 回顾性队列研究,数据来自台湾全民健康保险研究数据库1997至2011年,纳入1997至2010年新诊断类风湿关节炎患者,经1:1匹配后中药组和非中药组各4148例。
主要发现
- 中药组较非中药组缺血性卒中风险显著降低(aHR 0.67,95%CI 0.52-0.86)。
- 中药组中使用中药超过30天者较未超过30天者缺血性卒中风险更低(aHR 0.61,95%CI 0.40-0.91)。
- 桂枝芍药知母汤、舒筋活血汤和独活寄生汤可能与降低缺血性卒中风险相关。
临床怎么用
- 在类风湿关节炎患者中,可考虑在西药治疗基础上辅助使用中药以降低缺血性卒中风险,尤其对使用中药超过30天的患者可能获益更明显。
局限性
- 需要进一步随机对照试验来明确因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a retrospective cohort study to investigate the association between the risk of ischemic stroke (IS) and the use of Chinese herbal products (CHP) in combination with western medicine (WM) among patients with rheumatoid arthritis (RA). The data were sourced from the registry for beneficiaries, inpatient and ambulatory care claims, and Registry for Catastrophic Illness from the National Health Insurance Research Database (NHIRD) in Taiwan between 1997 and 2011. Patients, who were newly diagnosed with RA between 1997 and 2010, were classified as the CHP group or non-CHP group depending on the presence of absence the adjunctive use of CHP following a diagnosis of RA. A total of 4,148 RA patients were in both the CHP and non-CHP groups after 1:1 matching. Patients in the CHP group had a significantly lower risk of IS compared to patients in the non-CHP group (adjusted hazard ratio [aHR], 0.67; 95% confidence interval [CI], 0.52-0.86). In the CHP group, patients who used CHP for more than 30 days had a lower risk of IS than their counterparts (aHR: 0.61, 95% CI: 0.40-0.91). Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, Shu-Jin-Huo-Xie-Tang, and Du-Huo-Ji-Sheng-Tang might be associated with a lower risk of IS. Finally, the use of CHP in combination with WM was associated with a decreased risk of IS in patients with RA, especially among those who had used CHP for more than 30 days. A further randomized control trial is required to clarify the casual relationship between these results.
引用
- Shen HS, Chiang JH, Hsiung NH, et al. Adjunctive Chinese Herbal Products Therapy Reduces the Risk of Ischemic Stroke Among Patients With Rheumatoid Arthritis. Front Pharmacol. 2020. PMID: 32194408. doi:10.3389/fphar.2020.00169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。